Please check your internet connection and try again.
## Hepamerz (l-Ornithine l-Aspartate)
### Overview
Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate, used in the management of hepatic encephalopathy. It is believed to reduce ammonia levels by promoting its detoxification in the liver and peripheral tissues.
### Primary Indications
* Treatment of latent and overt hepatic encephalopathy associated with cirrhosis.
### Adult Dosing
* **Intravenous (IV) Infusion:**
* Standard dose: 5 grams (5000 mg) to 10 grams (10000 mg) administered as a slow infusion over 30-60 minutes, diluted in a suitable infusion solution (e.g., 5% dextrose, Ringer's lactate).
* Frequency: Typically given 1-3 times daily.
* Maximum dose: Up to 25 grams (25000 mg) per day may be used in severe cases, but this is not standard and depends on clinical response and tolerability.
* **Oral:**
* Doses vary widely in literature and clinical practice. Common starting doses range from 3 grams (3000 mg) three times daily to 6 grams (6000 mg) three times daily.
* Specific daily doses can range from 9 grams (9000 mg) to 18 grams (18000 mg) or higher, divided into multiple administrations.
### Pediatric Dosing
* No established pediatric dosing. Use is generally at the discretion of the clinician, often based on adult guidelines and adjusted for weight and clinical status.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment guidelines are well-established. Caution is advised.
* **Hepatic Impairment:** The drug is indicated for hepatic encephalopathy, so dose adjustments are typically based on clinical response rather than hepatic function itself.
### Contraindications
* Severe renal impairment (creatinine clearance < 25 mL/min).
* Hypersensitivity to L-ornithine or L-aspartate.
* Rarely, severe hyperammonemia due to other causes.
### Adverse Effects
* **Common:** Nausea, vomiting, abdominal discomfort, diarrhea.
* **Less Common:** Dizziness, headache, fatigue, skin rash, itching.
* **Rare:** Arrhythmias (with rapid IV infusion), hyperkalemia, hypernatremia.
### Key Drug Interactions
* No significant drug interactions are widely reported. However, caution may be warranted with other medications affecting electrolyte balance or renal function.
### Monitoring
* **Clinical:** Mental status, neurological signs, and symptoms of hepatic encephalopathy.
* **Laboratory:** Serum ammonia levels (though correlation with clinical status can be variable), electrolytes (sodium, potassium), renal function (BUN, creatinine), liver function tests.
### Clinical Pearls
* The oral formulation may be preferred for long-term management or when IV administration is not feasible.
* IV administration should be slow to minimize potential adverse effects like arrhythmias.
* Clinical improvement in encephalopathy is the primary guide for efficacy, not solely ammonia levels.
* Effectiveness and optimal dosing can vary significantly between individuals.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and guidelines for your specific patient population and indication. This information is not a substitute for professional medical advice.*
